Compound A Select compound… 5-Amino-1MQ Amlexanox AOD-9604 Argireline BPC-157 Buserelin Cagrilintide Carnosine Cerebrolysin CJC-1295 Cortexin Crystagen Dihexa DSIP Epithalon Follistatin 344 FOXO4-DRI GHK GHRP-2 GHRP-6 Glandokort Gonadorelin hCG HGH Fragment 176-191 Humanin IGF-1 DES IGF-1 LR3 Ipamorelin Kisspeptin KPV Liraglutide Livagen LL-37 Melanotan I Melanotan II MK-677 MOTS-c NAD+ Noopept NSI-189 Oxytocin P21 PEG-MGF Pinealon Pramlintide PT-141 Retatrutide Retinalamin Selank Semaglutide Semax Sermorelin SS-31 Svetinorm TB-500 Tesamorelin Tesofensine Thymalin Thymosin Alpha-1 Tirzepatide Triptorelin Ventfort Vesugen Vilon VIP
vs
Compound B Select compound… 5-Amino-1MQ Amlexanox AOD-9604 Argireline BPC-157 Buserelin Cagrilintide Carnosine Cerebrolysin CJC-1295 Cortexin Crystagen Dihexa DSIP Follistatin 344 FOXO4-DRI GHK GHK-Cu GHRP-2 GHRP-6 Glandokort Gonadorelin hCG HGH Fragment 176-191 Humanin IGF-1 DES IGF-1 LR3 Ipamorelin Kisspeptin KPV Liraglutide Livagen LL-37 Melanotan I Melanotan II MK-677 MOTS-c NAD+ Noopept NSI-189 Oxytocin P21 PEG-MGF Pinealon Pramlintide PT-141 Retatrutide Retinalamin Selank Semaglutide Semax Sermorelin SS-31 Svetinorm TB-500 Tesamorelin Tesofensine Thymalin Thymosin Alpha-1 Tirzepatide Triptorelin Ventfort Vesugen Vilon VIP
Molecular weight
390.35 g/mol
340.38 g/mol
Half-life
~30 minutes (estimated, limited pharmacokinetic data)
~1 hour (injectable); variable topical absorption
Admin routes
topical subcutaneous intradermal
Research areas
Telomere extension Anti-aging Pineal gland function Melatonin regulation Wound healing Diabetic retinopathy
Skin rejuvenation / anti-aging Wound healing Hair growth / follicle stimulation Lung fibrosis / COPD repair Anti-inflammatory Bone regeneration Nerve regeneration
Typical dosing
5000–10000 mcg · 1x daily · 10-20 days, 2-3x per year
200–500 mcg · 1x daily (injectable); 1-2x daily (topical) · 4-8 weeks (injectable); ongoing (topical)
FDA status
Not FDA-approved
Not FDA-approved as a drug. Available OTC in cosmetic formulations. Non-injectable GHK-Cu is on FDA's interim Category 1 list as of the 2026-05-14 document — Category 1 is titled "Under Evaluation" and carries enforcement discretion, not authorization. Injectable GHK-Cu is in no category and has no lawful compounding route. FDA intends to consult PCAC on GHK-Cu before the end of February 2027.
WADA status
Not listed
Not prohibited (as of 2026)
